Neurogene (NGNE) Debt to Equity (2013)
Neurogene (NGNE) reported Debt to Equity of -$0.03 for Q4 2013.
Neurogene (NGNE) Debt to Equity (2013) Analysis & Trends
Neurogene has reported Debt to Equity for 1 years, with the latest figure at -$0.03 in Q4 2013.
- For the quarter ending Q4 2013, Debt to Equity changed N/A year-over-year to -$0.03; the trailing twelve-month figure through Dec 2013 stood at -$0.03 (changed N/A YoY), and the FY2013 full-year result was -$0.03, changed N/A from the prior year.
- Debt to Equity for Q4 2013 stood at -$0.03.
- The five-year high for Debt to Equity was -$0.03 in Q4 2013, with the low at -$0.03 in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.32 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Neurogene | 216.17 Mn | 216.17 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | -0.03 |